论文部分内容阅读
Background:Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor(EGFR)mutation-positive advanced non-small-cell lung cancer(NSCLC).The efficacy and safety of osimertinib as adjuvant therapy are unknown.Methods:I